🎯 Key points for quick navigation: 00:18 *📜 Definitions of Oligometastatic Disease* - Oligometastatic disease is commonly defined by the "CHAARTED" definition published by Sweeney in 2015. - Other definitions include ESTRO, ACROP, and the HORRAD trial, which define oligometastatic disease differently, focusing on the number of lesions. 01:56 *📚 Treatment of the Primary Site* - The STAMPEDE trial revolutionized the approach to treating prostate cancer with concurrent oligometastatic disease. - Radiation treatment to the prostate has shown to improve survival rates in low metastatic burden cases. 06:05 *🧩 Impact of Prostate Radiation on Survival* - Radiation improved overall survival significantly in low burden oligometastatic disease, with median survival improvements. - High burden cases showed no difference, while both radiation schedules were effective. 11:58 *🔄 Metastasis Directed Therapy Insights* - Trials like STOMP, ORACLE, and others highlight the benefits of directing therapy at metastases. - Treatment of metastases extends ADT-free survival and progression-free survival, showing a clear benefit in various metrics. 15:29 *🔍 Future Directions and Conclusions* - Prostate treatment improves survival in low burden cases; metastasis-directed therapy can delay systemic treatment starts. - Clinical trials are needed for further insights, focusing on imaging and biological responses. Made with HARPA AI
🎯 Key points for quick navigation:
00:18 *📜 Definitions of Oligometastatic Disease*
- Oligometastatic disease is commonly defined by the "CHAARTED" definition published by Sweeney in 2015.
- Other definitions include ESTRO, ACROP, and the HORRAD trial, which define oligometastatic disease differently, focusing on the number of lesions.
01:56 *📚 Treatment of the Primary Site*
- The STAMPEDE trial revolutionized the approach to treating prostate cancer with concurrent oligometastatic disease.
- Radiation treatment to the prostate has shown to improve survival rates in low metastatic burden cases.
06:05 *🧩 Impact of Prostate Radiation on Survival*
- Radiation improved overall survival significantly in low burden oligometastatic disease, with median survival improvements.
- High burden cases showed no difference, while both radiation schedules were effective.
11:58 *🔄 Metastasis Directed Therapy Insights*
- Trials like STOMP, ORACLE, and others highlight the benefits of directing therapy at metastases.
- Treatment of metastases extends ADT-free survival and progression-free survival, showing a clear benefit in various metrics.
15:29 *🔍 Future Directions and Conclusions*
- Prostate treatment improves survival in low burden cases; metastasis-directed therapy can delay systemic treatment starts.
- Clinical trials are needed for further insights, focusing on imaging and biological responses.
Made with HARPA AI